Health Care • Biotechnology: Pharmaceutical Preparations
$370.33 ▼ -1.23
(-0.33%)
MKT CAP: $42.25B • VOL: 292.8K
52W L $254 52W H $389
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$311
MEDIAN
$415
MEAN
$422
HIGH
$504
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ONC TAPE
ONC // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $448.10 | $425.88 | 2025-02-14 | $337.00 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $466.62 | $436.99 | 2025-02-06 | $348.11 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $422.18 | $407.36 | 2025-01-29 | $355.52 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $377.74 | — | 2025-01-17 | $362.92 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $325.89 | $351.81 | 2025-01-09 | $329.59 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $440.69 | $385.14 | 2024-12-18 | $322.19 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $359.22 | $374.03 | 2024-12-04 | $344.41 | -4.3% | 48% | C |